List view / Grid view




Mundipharma launches Remsima®▼ (infliximab), a new-generation value-based monoclonal antibody, in six European markets

25 February 2015 | By Mundipharma

Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets...